Model 4 · 4 min read
Three Patents Were Enough
Quantity creates inventory. Value comes from curation.
Three patents. That is all it took. Stanford's biggest licensing success did not come from thousands of patents. It came from three foundational recombinant DNA patents: the Cohen-Boyer patents, first filed in 1974.
Everyone assumes bigger portfolio equals bigger payday. Sounds right. It isn't that simple.
Those patents were licensed to 468 companies over 17 years, generating approximately $255 million in licensing revenue by 2001. They helped enable products across biotechnology, from treatments for heart disease and anaemia to cancer, HIV and diabetes.
Meanwhile, Stanford's patent portfolio has grown into the thousands. Like most large portfolios, only a relatively small fraction generated significant licensing returns.
Here is the mental model that explains it: think curator, not hoarder. A museum is remembered for a handful of masterpieces, not the number of paintings hanging on its walls. Patent portfolios work the same way.
AUTM data consistently shows that licensing revenue is highly concentrated among a relatively small number of universities. And even within those institutions, commercial success is often driven by a small number of breakthrough inventions.
Four factors made the difference: quality (is the patent truly foundational, or simply another defensive filing?), industry alignment (Cohen-Boyer arrived just as modern biotechnology was emerging), commercialisation intelligence, and timing.
Portfolio size was never the variable that mattered. Curation is.